Phone Number
(800) 210-7017
(800) 210-7017
Here’s the honest picture most clinics won’t lay out for you: PRP has real, measurable evidence behind it for the common kind of pattern hair loss, but it’s an adjunct, not a cure. The studies that hold up show density climbing by roughly fifteen to forty hairs per square centimeter, with the strongest gains in people who still have living follicles to rescue. You’ll get the most out of it when you treat early and pair it with the proven drugs, not when you wait until the scalp’s already smooth.
Most controlled studies report PRP raising hair density by fifteen to forty hairs per square centimeter in early-to-moderate androgenetic alopecia, positioning it as a real but adjunctive therapy that requires ongoing maintenance rather than a permanent cure.
When you read the better-built trials, the PRP side of the scalp consistently beats the saline or untreated side, and the split-scalp design is what makes that believable. Each patient is their own control, so the result isn’t just one lucky group regressing toward the mean. What should matter to you is that the gains show up in terminal hairs, the thick pigmented ones you actually see in the mirror, not just fuzz.
The strongest split-scalp trials report PRP increasing terminal hair density by fifteen to forty hairs per square centimeter within three to six months, with each patient serving as their own control.
A lot of clinics throw around the phrase “proven results” without telling you how anyone measured the proof, and the tools matter because they answer different questions. The number that should carry the most weight with you is the one scored by an evaluator who doesn’t know which photo is “before” and which is “after,” because that’s the only way to strip out the wishful thinking that creeps in when a provider grades their own work.
Blinded global photographic assessment, where independent evaluators score before-and-after images without knowing which is which, is regarded as the gold standard because it removes the bias of a clinician judging their own work.
Candidate selection predicts your result more than almost anything else, and the rule underneath it is simple: PRP can only revive follicles that are still alive. Once the scalp goes smooth and shiny and the follicular openings are gone, there’s nothing left for the growth factors to act on, which is why how long you’ve been losing hair matters far more than your age.
PRP works best in early-to-moderate androgenetic alopecia where viable miniaturized follicles still exist, and clinicians confirm living follicles by trichoscopy before committing a patient to a treatment course.
Don’t think of PRP as the thing that beats the drugs. The published head-to-head data put it roughly even with minoxidil on density, and the most reliable finding across the literature is that stacking treatments wins. The drugs hit the hormonal and vascular drivers while PRP drops in a localized burst of growth factors, so they add up instead of competing.
| Criteria | PRP | Minoxidil | Finasteride | Transplant |
|---|---|---|---|---|
| Mechanism | Growth-factor burst | Vascular/follicular | Blocks DHT | Moves follicles |
| Role | Adjunctive, non-surgical | First-line topical | Most powerful drug (men) | Later-stage surgery |
| Combination value | Boosts the others | Boosted by PRP | Boosted by PRP | PRP aids graft survival |
| Safety burden | Autologous, repeat injections | Daily use, irritation | Sexual side-effect risk | Surgical recovery |
Across head-to-head studies PRP delivers density gains roughly comparable to minoxidil, but combining it with minoxidil or finasteride consistently outperforms any single agent because the mechanisms are additive.
I don’t want you walking in thinking the evidence is airtight, because it isn’t, and the biggest crack is that “PRP” in one study can be a completely different preparation than “PRP” in another. Platelet concentration, white-cell content, activation, injection depth, and session spacing all swing wildly, which means the field is quietly comparing different treatments under one name. On top of that, most trials are small and short, so they can’t tell you whether the results hold past a year.
The absence of a standardized preparation protocol means published PRP trials often compare fundamentally different interventions under one name, so systematic reviews rate the overall evidence as moderate at best.
The logic here is straightforward once you see it: platelets are packed with growth factors, so injecting a concentrated payload into the scalp delivers a signaling burst right where dormant follicles need it. Think of it less as feeding the hair and more as waking it up, nudging resting follicles back into their active growth phase.
PRP concentrates platelet growth factors such as VEGF and IGF that prolong the follicle’s active growth phase and push resting follicles back into anagen, the central event that partially reverses androgenetic miniaturization.
Here’s the part that defines the commitment: PRP is maintenance, not a one-time fix. It doesn’t switch off the hormonal and genetic process that’s shrinking your follicles, it just keeps pushing back against it, so the schedule never really ends. Stop entirely and the gains fade over the following six to twelve months as the miniaturization quietly reasserts itself.
PRP gains fade over six to twelve months if treatment stops entirely, so sustaining results requires maintenance injections every three to six months, ideally paired with ongoing minoxidil or finasteride.
Two clinics can both call it PRP and hand you genuinely different treatments, and that’s why your result depends so heavily on whose equipment and protocol you’re sitting under. The variables aren’t minor tweaks; they’re the difference between a preparation that works and one that underperforms, with concentration being the single most studied lever.
Effective PRP concentrates platelets to roughly three to six times whole-blood baseline, and because the field never standardized concentration, activation, and injection depth, a patient’s results depend heavily on their provider’s specific protocol.
The number worth anchoring on is that roughly two-thirds to three-quarters of well-selected patients show a positive response on objective or photographic assessment. Just keep the gap in mind between a statistically significant group average and a result you can actually notice in the mirror, because those aren’t the same thing, and a meaningful minority get no perceptible benefit at all.
Roughly two-thirds to three-quarters of appropriately selected patients with early-to-moderate androgenetic alopecia show a positive response, and the first signs typically appear within two to three months, with no movement by four to six months signaling likely failure.
